The impact of immune checkpoint inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a meta-analysis

The impact of immune checkpoint inhibitors on prognosis in unresectable hepatocellular carcinoma treated with TACE and lenvatinib: a meta-analysis

BackgroundCombination of multiple therapies is a common approach to treating patients with unresectable hepatocellular carcinoma (uHCC). The impact of immune checkpoint inhibitors (ICIs) on prognosis in uHCC patients treated with transarterial chemoembolization (TACE) and lenvatinib remains unclear....

Full description

Saved in:

Bibliographic Details
Main Authors:	Wei Zhang, Zirong Liu, Hongjin Liu, Zhangkan Huang, Xiaozhun Huang, Lin Xu, Xu Che, Zhengyin Zhan
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-05-01
Series:	Frontiers in Immunology
Subjects:	hepatocellular carcinoma transarterial chemoembolization lenvatinib immune checkpoint inhibitor PD-1 inhibitor
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1573505/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

TACE Combined with Lenvatinib-PD-1 Versus TACE Monotherapy as Conversion Therapy Before Liver Resection in Unresectable Hepatocellular Carcinoma: A Retrospective, Propensity Score Matching Study
by: Lu C, et al.
Published: (2025-07-01)

Comparative analysis of efficacy and safety between D-TACE + HAIC + lenvatinib and D-TACE + lenvatinib in the treatment of unresectable massive hepatocellular carcinoma
by: Haohao Lu, et al.
Published: (2024-11-01)

Efficacy and Safety of Lenvatinib Plus Programmed Death-1 Inhibitors with or Without Transarterial Chemoembolization in the Treatment of Unresectable Hepatocellular Carcinoma
by: Jin M, et al.
Published: (2024-11-01)

Efficacy and safety of TACE combined with lenvatinib and PD-1 Inhibitor in intermediate-stage HCC exceeding the up-7 criteria: a retrospective cohort study
by: Miao Xue, et al.
Published: (2025-06-01)

Efficacy, safety, and biomarker analysis of TACE combined with lenvatinib plus sintilimab in unresectable hepatocellular carcinoma: a real-world study
by: Lingzhan Meng, et al.
Published: (2024-11-01)

Efficacy and safety of lenvatinib plus transarterial chemoembolization with or without programmed death-1 inhibitors in the treatment of intermediate or advanced hepatocellular carcinoma: a systematic review and meta-analysis
by: Yongfa Lei, et al.
Published: (2025-07-01)

First-line treatment of hepatocellular carcinoma: a propensity-matched analysis of tyrosine kinase inhibitors combined with TACE, with or without PD-1 inhibitors
by: Yanjun Shen, et al.
Published: (2025-05-01)

Transarterial chemoembolization combined with tyrosine kinase inhibitors and/or immune checkpoint inhibitors induced hypothyroidism is associated with improved overall survival in hepatocellular carcinoma
by: Shengyuan Xu, et al.
Published: (2025-05-01)

Prognostic impact of tace combined with sorafenib or lenvatinib followed by regorafenib in recurrent hepatocellular carcinoma after liver transplantation: a retrospective study
by: Zhao-dan Ye, et al.
Published: (2025-07-01)

Efficacy Analysis of TACE Combined with Lenvatinib and PD-1 Inhibitors in the Treatment of Hepatitis B Virus-Related Unresectable Hepatocellular Carcinoma
by: Yu J, et al.
Published: (2025-07-01)

Deep learning of pretreatment multiphase CT images for predicting response to lenvatinib and immune checkpoint inhibitors in unresectable hepatocellular carcinoma
by: Nan-Qing Liao, et al.
Published: (2024-12-01)

Efficacy and safety of TACE combined with TKIs and PD-1 inhibitors in HCC patients with prior TIPS
by: Kai Xiong, et al.
Published: (2025-04-01)

Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial
by: Jie Li, et al.
Published: (2025-07-01)

Comparative Effectiveness and Safety of Molecular Targeted Therapy Plus PD-(L)1 with or without TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Study
by: Liu J, et al.
Published: (2025-07-01)

Efficacy and safety of TACE-HAIC combined with tyrosine kinase inhibitors and immune checkpoint inhibitors for the patients with BCLC-defined stage B-C HCC
by: Bowen Liu, et al.
Published: (2025-07-01)

A real-world study of the efficacy of second-line treatment of unresectable hepatocellular carcinoma with esophagogastric varices after progression on first-line lenvatinib combined with PD-1 inhibitor
by: Saifeng Li, et al.
Published: (2025-03-01)

Increment of Skeletal Muscle Mass Predicts Survival Benefit for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization Combining Molecular Targeted Agents and Immune Checkpoint Inhibitors
by: Chen W, et al.
Published: (2025-02-01)

Mono‐TKI and TKI Plus ICI in Unresectable Hepatocellular Carcinoma Progression on First‐Line Treatment of Lenvatinib: A Real‐World Study
by: Xue Yin, et al.
Published: (2025-03-01)

Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for unresectable HCC: a meta-analysis
by: Min Wei, et al.
Published: (2024-12-01)

RALOX-HAIC (raltitrexed + oxaliplatin) combined with lenvatinib improves survival and safety in elderly patients with unresectable hepatocellular carcinoma
by: Haohao Lu, et al.
Published: (2025-05-01)

Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular carcinoma: a systematic review and meta-analysis
by: Hengyu Tian, et al.
Published: (2025-04-01)

Optimal sequencing of locoregional and systemic therapies for intermediate and advanced hepatocellular carcinoma: a network meta-analysis
by: Wei Lu, et al.
Published: (2025-06-01)

PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma
by: Jitong Zhou, et al.
Published: (2025-07-01)

The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
by: Wu Y, et al.
Published: (2025-02-01)

Benefits of step-by-step debulking microwave ablation for huge unresectable hepatocellular carcinoma patients after transcatheter arterial chemoembolization refractoriness
by: Tao Huang, et al.
Published: (2022-12-01)

Clinical efficacy and safety of TACE combined with lenvatinib and PD-1 antibody in treatment of intermediate-advanced hepatocellular carcinoma
by: JIANG Jiayun, et al.
Published: (2024-11-01)

Clinical outcomes of transarterial chemoembolization combined with durvalumab for advanced and metastatic biliary tract cancer
by: Yuefeng Hu, et al.
Published: (2025-12-01)

Community characteristics and relationship between gut microbiota and intratumoral microbiota in hepatocellular carcinoma
by: Huangpeng Lin, et al.
Published: (2025-01-01)

Efficacy and safety of D-TACE followed by D-RFA for unresectable large hepatocellular carcinoma
by: Qingqing Pang, et al.
Published: (2025-07-01)

The Association between Peripheral Th17, Th1, IL-17, and IFN-γ Levels and TACE Response in Patients with Unresectable Hepatocellular Carcinoma with or without Cirrhosis
by: Irsan Hasan, et al.
Published: (2020-12-01)

The Association between Peripheral Th17, Th1, IL-17, and IFN-γ Levels and TACE Response in Patients with Unresectable Hepatocellular Carcinoma with or without Cirrhosis
by: Irsan Hasan, et al.
Published: (2020-12-01)

Hepatic arterial infusion chemotherapy (HAIC) plus Lenvatinib and PD-1 inhibitors versus systemic chemotherapy for unresectable intrahepatic cholangiocarcinoma
by: Qingyu Xu, et al.
Published: (2025-05-01)

Lenvatinib-induced pemphigus erythematosus in hepatocellular carcinoma: a unique case report
by: Xiaoqing Li, et al.
Published: (2025-03-01)

DCP as a biomarker for TACE efficacy in hepatocellular carcinoma
by: Hui Xie, et al.
Published: (2025-07-01)

Efficacy and Safety of Transarterial Chemoembolization Combined with Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib for Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven: A Multicentre, Retrospective Propensity Score Matching Analysis
by: Zhong S, et al.
Published: (2025-03-01)

Unresectable ectopic hepatocellular carcinoma in the left sub-diaphragmatic area and retroperitoneum treated with TACE: case report and literature review
by: Chao-Bang Xie, et al.
Published: (2025-12-01)

A Transcriptomic Biomarker for Predicting the Response to TACE Correlates with the Tumor Microenvironment and Radiomics Features in Hepatocellular Carcinoma
by: Wang C, et al.
Published: (2024-11-01)

The efficacy of transarterial chemoembolization combined with helical iodine-125 seed implant, lenvatinib and PD-1 inhibitors in patients with hepatocellular carcinoma complicated by main portal vein tumor thrombus: a retrospective study
by: Jia-Wen Lin, et al.
Published: (2025-05-01)

TRACE Model: Predicting Treatment Response to Transarterial Chemoembolization in Unresectable Hepatocellular Carcinoma
by: Wang W, et al.
Published: (2025-01-01)

Development of a Nomogram for Prognostic Prediction of Large Hepatocellular Carcinoma With HBV After TACE Combined Conversion Therapy
by: Xu W, et al.
Published: (2025-04-01)